Pediatric Drugs

Papers
(The H4-Index of Pediatric Drugs is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus69
Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy43
Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting38
Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-234
Assessment and Management of Acute Disseminated Encephalomyelitis (ADEM) in the Pediatric Patient30
Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children30
Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria29
Dupilumab Treatment in Children Aged 6–11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study28
Lidocaine Infusions for Pain Management in Pediatrics22
The Use of Linaclotide in Children with Functional Constipation or Irritable Bowel Syndrome: A Retrospective Chart Review22
Phentermine/Topiramate: Pediatric First Approval21
Sodium Thiosulfate: Pediatric First Approval20
Benefits and Risks of Antidepressant Drugs During Pregnancy: A Systematic Review of Meta-analyses20
Viloxazine: Pediatric First Approval19
An Update on CFTR Modulators as New Therapies for Cystic Fibrosis19
Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance19
Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years19
Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients19
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis18
An Update of Pharmacological Management in Children with Functional Constipation18
Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial18
0.032363891601562